Sign in
CompletedPhase 4

Effect of Itopride on Semaglutide Gastroparesis

Key facts

Who runs it
Ain Shams University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
60 people enrolled
Started
1 Jan 2026
Ended
30 Jul 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Itopride HCI 50 mg
  • Placebo
Record updated
25 September 2026

Who can take part

Age
40 years to 60 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • American Society of Anesthesiologists grade I- III
  • Age: 40-60 years
  • BMI: 20-30 kg/m2
  • Diabetic patients on semaglutide (0.5-1mg) SC weekly
  • Undergoing elective hysterectomy

Who cannot take part

  • history of upper abdominal surgery or the presence of hiatal hernia
  • History of allergy to Itopride
  • History of cardiac arrhythmia or abnormal ECG
  • Neurologic diseases (including Parkinson's disease and multiple sclerosis)
  • Hepatic or renal failure
  • Other medications inducing gastroparesis (opioids, proton pump inhibitors, tricyclic antidepressants, calcium channel blockers, antipsychotic medications, and lithium)
  • Declining to give written informed consent

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Semaglutide delays gastric emptying and increases the risk of aspiration with anesthesia; So, the addition of prokinetics as Itopride, could enhance gastric emptying and hasten surgery.

Read full original descriptionShow less

The investigator will evaluate the effect of Itopride on Semaglutide-induced gastroparesis and residual gastric contents after 8 hours of fasting by gastric ultrasound before anesthesia.

The 2 groups in the trial

  • Itopride HCLExisting treatment, for comparison

    Daily oral 50mg Itopride tablet TID, 1 hour before meals for 7 days

    Treatment: Itopride HCI 50 mg

  • PlaceboPlacebo, for comparison

    Daily placebo tablet TID, 1 hour before meals for 7 days

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Does Itopride Improve Semaglutide Induced Gastroparesis Ultrasound Before Anesthesia? Randomized Controlled Trial
Record updated
25 September 2026